NCT00026312 · OUTCOME

Incidence of Toxicities Assessed Using Common Terminology Criteria for Adverse Events Version 4.0

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma · Source last updated 2026-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Proportion
Interval / dispersion: 95% Confidence Interval
Time frame: From enrollment to follow-up

What was measured

Proportion of patients experiencing at least one Grade 3 or higher toxicity.

Analysis population: Eligible patients enrolled prior to halting of randomization.

Groups in this outcome

Regimen A

Randomized to Regimen A - RA Only

Regimen B

Patients that received RA + Immunotherapy before halting of randomization

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Regimen A	112
Regimen B	141

Reported measurements

Source class 1

Values in Proportion · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Regimen A	0.64	Not reported	0.55	0.73	Not reported
Regimen B	0.94	Not reported	0.90	0.98	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
0.55
upper Limit
0.73
value
0.64
group Id
OG001
lower Limit
0.90
upper Limit
0.98
value
0.94

denoms

counts
group Id
OG000
value
112
group Id
OG001
value
141
units
Participants

description

Proportion of patients experiencing at least one Grade 3 or higher toxicity.

dispersion Type

95% Confidence Interval

groups

description
Randomized to Regimen A - RA Only
id
OG000
title
Regimen A
description
Patients that received RA + Immunotherapy before halting of randomization
id
OG001
title
Regimen B

param Type

NUMBER

population Description

Eligible patients enrolled prior to halting of randomization.

reporting Status

POSTED

time Frame

From enrollment to follow-up

title

Incidence of Toxicities Assessed Using Common Terminology Criteria for Adverse Events Version 4.0

type

SECONDARY

unit Of Measure

Proportion

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice